A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset

Multiple sclerosis (MS) is the most common cause for sustained disability in young adults, yet treatment options remain very limited. Although numerous therapeutic approaches have been effective in rodent models of experimental autoimmune encephalomyelitis (EAE), only few proved to be beneficial in...

Full description

Saved in:
Bibliographic Details
Published in:Brain pathology (Zurich, Switzerland) Switzerland), 2016-07, Vol.26 (4), p.452-464
Main Authors: Stassart, Ruth Martha, Helms, Gunther, Garea-Rodríguez, Enrique, Nessler, Stefan, Hayardeny, Liat, Wegner, Christiane, Schlumbohm, Christina, Fuchs, Eberhard, Brück, Wolfgang
Format: Article
Language:English
Subjects:
Animals
Callithrix
common marmoset
Cytokines
Cytokines - administration & dosage
Cytokines - immunology
demyelination
Encephalomyelitis, Autoimmune, Experimental
experimental autoimmune encephalomyelitis
Female
immunomodulation
laquinimod
Male
multiple sclerosis
Myelin-Oligodendrocyte Glycoprotein - administration & dosage
Myelin-Oligodendrocyte Glycoprotein - immunology
Rodents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis (MS) is the most common cause for sustained disability in young adults, yet treatment options remain very limited. Although numerous therapeutic approaches have been effective in rodent models of experimental autoimmune encephalomyelitis (EAE), only few proved to be beneficial in patients with MS. Hence, there is a strong need for more predictive animal models. Within the past decade, EAE in the common marmoset evolved as a potent, alternative model for MS, with immunological and pathological features resembling more closely the human disease. However, an often very rapid and severe disease course hampers its implementation for systematic testing of new treatment strategies. We here developed a new focal model of EAE in the common marmoset, induced by myelin oligodendrocyte glycoprotein (MOG) immunization and stereotactic injections of proinflammatory cytokines. At the injection site of cytokines, confluent inflammatory demyelinating lesions developed that strongly resembled human MS lesions. In a proof‐of‐principle treatment study with the immunomodulatory compound laquinimod, we demonstrate that targeted EAE in marmosets provides a promising and valid tool for preclinical experimental treatment trials in MS research.
ISSN:1015-6305
1750-3639
DOI:10.1111/bpa.12292